Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population

Journal of Cardiology

Volumn 61, Issue 2, 2013, Pages 169-174

  Matsue, Yuya ^a   Suzuki, Makoto ^a   Seya, Mie ^a   Iwatsuka, Ryota ^a   Mizukami, Akira ^a   Nagahori, Wataru ^a   Ohno, Masakazu ^a   Matsumura, Akihiko ^a   Hashimoto, Yuji ^a  

^a KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Diuretics; Renal function; Vasopressin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HEMOGLOBIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; SODIUM; SPIRONOLACTONE; TOLVAPTAN; VASODILATOR AGENT;

ACUTE HEART FAILURE; AGED; ARTICLE; BODY MASS; BRAIN INFARCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DIURESIS; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; SMOKING; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; WORSENING RENAL FUNCTION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BENZAZEPINES; COMPARATIVE EFFECTIVENESS RESEARCH; CREATININE; DIURESIS; DIURETICS; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; HYPERNATREMIA; KIDNEY FUNCTION TESTS; MALE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; TIME FACTORS; URINATION;

EID: 84873090665     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.08.020     Document Type: Article

References (35)

1. Felker G.M., O'Connor C.M., Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circ Heart Fail 2009, 2:56-62.
2. Heywood J.T., Fonarow G.C., Costanzo M.R., Mathur V.S., Wigneswaran J.R., Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007, 13:422-430.
3. Hillege H.L., Nitsch D., Pfeffer M.A., Swedberg K., McMurray J.J., Yusuf S., Granger C.B., Michelson E.L., Ostergren J., Cornel J.H., de Zeeuw D., Pocock S., van Veldhuisen D.J. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators.
4. Hamaguchi S., Tsuchihashi-Makaya M., Kinugawa S., Yokota T., Ide T., Takeshita A., Tsutsui H., JCARE-CARD Investigators Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009, 73:1442-1447.
5. Hosoda J., Ishikawa T., Matsushita K., Matsumoto K., Kimura Y., Miyamoto M., Ogawa H., Takamura T., Sugano T., Ishigami T., Uchino K., Kimura K., Umemura S. Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy. J Cardiol 2012, http://dx.doi.org/10.1016/j.jjcc.2012.06.001.
6. Shiba N., Shimokawa H. Chronic kidney disease and heart failure-bidirectional close link and common therapeutic goal. J Cardiol 2011, 57:8-17.
7. Schrier R.W., Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577-585.
8. Ahmed A., Campbell R.C. Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin 2008, 4:387-399.
9. Cuffe M.S., Califf R.M., Adams K.F., Benza R., Bourge R., Colucci W.S., Massie B.M., O'Connor C.M., Pina I, Quigg R., Silver M.A., Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators.
10. Iwanaga Y., Miyazaki S. Heart failure, chronic kidney disease, and biomarkers-an integrated viewpoint. Circ J 2010, 74:1274-1282.
11. Tang W.H., Mullens W. Cardiorenal syndrome in decompensated heart failure. Heart 2010, 96:255-260.
12. Miyazaki T., Yamamura Y., Onogawa T., Nakamura S., Kinoshita S., Nakayama S., Fujiki H., Mori T. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 2005, 146:3037-3043.
13. Gheorghiade M., Gattis W.A., O'Connor C.M., Adams K.F., Elkayam U., Barbagelata A., Ghali J.K., Benza R.L., McGrew F.A., Klapholz M., Ouyang J., Orlandi C. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.
14. Forman D.E., Butler J., Wang Y., Abraham W.T., O'Connor C.M., Gottlieb S.S., Loh E., Massie B.M., Rich M.W., Stevenson L.W., Young J.B., Krumholz H.M. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004, 43:61-67.
15. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993, 88:107-115.
16. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
17. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., Yamagata K., Tomino Y., Yokoyama H., Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992. Collaborators developing the Japanese equation for estimated GFR.
18. Mehta R.L., Kellum J.A., Shah S.V., Molitoris B.A., Ronco C., Warnock D.G., Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31. Acute Kidney Injury Network.
19. Francis G.S., Benedict C., Johnstone D.E., Kirlin P.C., Nicklas J., Liang C.S., Kubo S.H., Rudin-Toretsky E., Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
20. Francis G.S., Siegel R.M., Goldsmith S.R., Olivari M.T., Levine T.B., Cohn J.N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985, 103:1-6.
21. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987, 57:17-22.
22. Peacock W.F., Costanzo M.R., De Marco T., Lopatin M., Wynne J., Mills R.M., Emerman C.L. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009, 113:12-19. ADHERE Scientific Advisory Committee and Investigators.
23. Fonarow G.C., Adams K.F., Abraham W.T., Yancy C.W., Boscardin W.J. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572-580.
24. Brater D.C. Diuretic therapy. N Engl J Med 1998, 339:387-395.
25. Wang D.J., Gottlieb S.S. Diuretics: still the mainstay of treatment. Crit Care Med 2008, 36:S89-S94.
26. Kon V., Yared A., Ichikawa I. Role of renal sympathetic nerves in mediating hypoperfusion of renal cortical microcirculation in experimental congestive heart failure and acute extracellular fluid volume depletion. J Clin Invest 1985, 76:1913-1920.
27. Goldberg A., Hammerman H., Petcherski S., Zdorovyak A., Yalonetsky S., Kapeliovich M., Agmon Y., Markiewicz W., Aronson D. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J 2005, 150:330-337.
28. Newsome B.B., Warnock D.G., McClellan W.M., Herzog C.A., Kiefe C.I., Eggers P.W., Allison J.J. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008, 168:609-616.
29. Krumholz H.M., Chen Y.T., Vaccarino V., Wang Y., Radford M.J., Bradford W.D., Horwitz R.I. Correlates and impact on outcomes of worsening renal function in patients≥65 years of age with heart failure. Am J Cardiol 2000, 85:1110-1113.
30. Logeart D., Tabet J.Y., Hittinger L., Thabut G., Jourdain P., Maison P., Tartiere J.M., Solal A.C. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008, 127:228-232.
31. Latchamsetty R., Fang J., Kline-Rogers E., Mukherjee D., Otten R.F., LaBounty T.M., Emery M.S., Eagle K.A., Froehlich J.B. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol 2007, 99:939-942.
32. Miyazaki T., Fujiki H., Yamamura Y., Nakamura S., Mori T. Tolvaptan: an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev 2007, 25:1-13.
33. Costello-Boerrigter L.C., Smith W.B., Boerrigter G., Ouyang J., Zimmer C.A., Orlandi C., Burnett J.C. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006, 290:F273-F278.
34. Konstam M.A., Gheorghiade M., Burnett J.C., Grinfeld L., Maggioni A.P., Swedberg K., Udelson J.E., Zannad F., Cook T., Ouyang J., Zimmer C., Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297:1319-1331. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators.
35. Jose P., Skali H., Anavekar N., Tomson C., Krumholz H.M., Rouleau J.L., Moye L., Pfeffer M.A., Solomon S.D. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006, 17:2886-2891.